Stockscreener 앱 받기
15.08
4.80%
-0.76
전일 마감가:
$15.84
열려 있는:
$15.95
하루 거래량:
869.16K
Relative Volume:
0.68
시가총액:
$1.25B
수익:
$46.02M
순이익/손실:
$-70.80M
주가수익비율:
-8.2857
EPS:
-1.82
순현금흐름:
$-1.61M
1주 성능:
-7.09%
1개월 성능:
-10.93%
6개월 성능:
+49.90%
1년 성능:
+107.43%
1일 변동 폭
$15.01
$16.18
1주일 범위
$15.01
$17.61
52주 변동 폭
$3.91
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
명칭
Eyepoint Inc
전화
617-926-5000
주소
480 PLEASANT STREET, WATERTOWN, MA
EYPT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
15.08 | 1.31B | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-17 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-07 | 개시 | Citigroup | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-28 | 개시 | Jefferies | Buy |
| 2024-01-22 | 개시 | JP Morgan | Overweight |
| 2023-11-02 | 개시 | Mizuho | Buy |
| 2023-04-21 | 개시 | Robert W. Baird | Outperform |
| 2022-07-07 | 개시 | Chardan Capital Markets | Buy |
| 2021-03-01 | 개시 | Cowen | Outperform |
| 2021-01-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-04-06 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | 재개 | Laidlaw | Buy |
| 2019-09-12 | 개시 | Guggenheim | Buy |
모두보기
Eyepoint Inc 주식(EYPT)의 최신 뉴스
EyePoint (EYPT) Issues Stock Options to New Employees - GuruFocus
EyePoint, Inc. (EYPT) Stock Analysis: Exploring the 127.80% Potential Upside in a Challenging Market - DirectorsTalk Interviews
EyePoint, Inc. Grants Stock Options to New Employees as Inducement Awards - Quiver Quantitative
EyePoint offers stock options to three new hires for 13,900 shares - Stock Titan
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap UpTime to Buy? - MarketBeat
Equities Analysts Issue Forecasts for EYPT Q3 Earnings - MarketBeat
EyePoint, Inc. Provides Corporate Update and Anticipated Milestones for 2026 - VisionMonday.com
Responsive Playbooks and the EYPT Inflection - Stock Traders Daily
Can EyePoint Pharmaceuticals Inc. stock maintain growth trajectory2025 Technical Patterns & Safe Capital Growth Stock Tips - Улправда
Is EyePoint Pharmaceuticals Inc. stock overvalued by current metricsJuly 2025 Weekly Recap & AI Driven Price Predictions - Улправда
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 4.6%Here's Why - MarketBeat
Will EyePoint Pharmaceuticals Inc. stock remain a Wall Street favoriteGrip and Outsole Review & road comfort picks for daily use - Улправда
EyePoint, Inc. (EYPT) Stock Analysis: Exploring the 111% Upside Potential Amidst Strategic R&D - DirectorsTalk Interviews
How sustainable is EyePoint Pharmaceuticals Inc. stock dividend payoutMarket Performance Report & Safe Entry Point Identification - ulpravda.ru
How EyePoint Pharmaceuticals Inc. stock reacts to inflationary pressuresJuly 2025 Gainers & Real-Time Volume Analysis Alerts - ulpravda.ru
Aug Ideas: Is EyePoint Pharmaceuticals Inc. stock affected by interest rate hikes2025 Year in Review & Safe Investment Capital Preservation Plans - Улправда
Is EyePoint Pharmaceuticals Inc. stock affected by interest rate hikesPortfolio Value Summary & High Conviction Buy Zone Alerts - ulpravda.ru
Will EyePoint Pharmaceuticals Inc. stock continue dividend increasesMarket Volume Report & Entry Point Confirmation Alerts - Улправда
Ramiro Ribeiro Sells 42,544 Shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock - MarketBeat
Eyepoint Insider Sold Shares Worth $727,319, According to a Recent SEC Filing - marketscreener.com
EyePoint Chief Medical Officer Sells All Common Stock Holdings - TradingView — Track All Markets
EyePoint, Inc.Common Stock (NQ: EYPT - FinancialContent
Mizuho reiterates Outperform rating on EyePoint stock with $33 target By Investing.com - Investing.com Canada
Mizuho reiterates Outperform rating on EyePoint stock with $33 target - Investing.com
RBC Capital reiterates Outperform rating on EyePoint stock at $39 target - Investing.com Nigeria
RBC Capital reiterates Outperform rating on EyePoint stock at $39 target By Investing.com - Investing.com India
EyePoint’s Phase 3 trials for DURAVYU in wet AMD on track for mid-2026 data - Investing.com
EyePoint’s Phase 3 trials for DURAVYU in wet AMD on track for mid-2026 data By Investing.com - Investing.com South Africa
EyePoint, Inc. Advances DURAVYU in Pivotal Phase 3 Trials for Wet AMD and DME with Key Milestones Expected in 2026 - Quiver Quantitative
Uveitis Treatment Market to Reach US$ 1,258.35million | CAGR - openPR.com
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026 - GlobeNewswire
PRN_FinancialWrapper | PR NewswireEyePoint, Inc.Common Stock (Nasdaq:EYPT) Stock Quote - FinancialContent
EYPT (EyePoint) Days Payable : 1,883.28 (As of Sep. 2025) - GuruFocus
Is EyePoint Pharmaceuticals the Next Sleeper Stock Legend or Just Overhyped Noise? - AD HOC NEWS
Institutional Investors in EyePoint, Inc. (NASDAQ:EYPT) See US$67m Decrease in Market Cap Last Week, Although Long-term Gains Have Benefitted Them. - 富途牛牛
EyePoint (EYPT) price target increased by 10.87% to 36.80 - MSN
What drives EyePoint Pharmaceuticals Inc PV3B stock priceSell Signals and Alerts & Top Analyst Picks Available for Free - earlytimes.in
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 6.1%Here's What Happened - MarketBeat
The Year-End 2025 Biotech Rally And What It Means For 2026 - Benzinga
Understanding the Setup: (EYPT) and Scalable Risk - Stock Traders Daily
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of "Buy" by Analysts - MarketBeat
127,489 Shares in Eyepoint Pharmaceuticals, Inc. $EYPT Purchased by Corient Private Wealth LLC - MarketBeat
Why EyePoint (EYPT) Is Up 9.6% After Upbeat Earnings Revisions And Momentum SignalsAnd What's Next - Sahm
EyePoint (EYPT): Assessing Valuation After Earnings Upgrades and Strong Momentum-Driven Share Gains - Yahoo Finance
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 6.2%Time to Sell? - MarketBeat
EyePoint Earnings Notes - Trefis
EyePoint (EYPT) Is Up 9.01% in One Week: What You Should Know - Yahoo Finance
3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026 - Zacks Investment Research
Would You Still Hold EyePoint Stock If It Fell 30%? - Trefis
Will EyePoint Pharmaceuticals Inc. stock rally after Fed decisionsWeekly Risk Summary & Technical Analysis for Trade Confirmation - Улправда
EyePoint (EYPT) Price Target Increased by 10.87% to 36.80 - Nasdaq
Eyepoint Inc (EYPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):